Rare Oncology
Pipeline
Pre-clinical
Ph 1
Ph 2
Ph 3
Approval

CAN008

Indication:
Glioblastoma
License Partner:
License Region:

Greater China

CAN008

Description: CAN008 is a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to CD95L.

Indication: Glioblastoma (GBM), the most common primary intracranial tumour and the most invasive and malignant in nature

Status: Phase 2 in China

Trial registration: ClinicalTrials.gov NCT05447195

Ownership: Exclusive Greater China license from Apogenix

Rare Diseases
Pipeline
Pre-clinical
Ph 1
Ph 2
Ph 3
Approval

Hunterase®

Indication:
Mucopolysaccharidosis type II (MPS II) or Hunter syndrome
License Partner:
License Region:

Greater China

Hunterase®

Description: Hunterase®, (iduronidase-2-sulfatase) is a recombinant human enzyme replacement therapy (ERT).

Indication: Mucopolysaccharidosis type II (MPS II) or Hunter syndrome

Status: Hunterase is designated an orphan drug in the United States and Korea and is marketed in 12 countries. Hunterase was approved for marketing in China in September 2020.

Ownership: Exclusive license to develop and commercialize in Greater China from South Korea’s GC Pharma

CAN108

Indication:
ALGS
License Partner:
License Region:

Greater China

Indication:
PFIC
License Partner:
License Region:

Greater China

Indication:
BA
License Partner:
License Region:

Greater China

CAN108 (Maralixibat)

Description: CAN108 is an orally administered small molecule ASBT inhibitor.

Indication: multiple rare cholestatic liver diseases, including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA)

Status: USA FDA Approved, China NDA filed (ALGS) and EMA filed in EU (PFIC); Phase IIb (BA)

Ownership: Exclusive Greater China license from Mirum Pharmaceuticals

Note: For BA, we are supporting the patient recruitment and clinical site management in China for a global Phase II clinical trial initiated by our license partner in the U.S. and Europe. IND approval was obtained from the NMPA in May 2021 and we plan to begin patient enrolment in China as part of the global Phase II trial.

CAN106

Indication:
Paroxysmal Nocturnal Hemoglobinuria
License Partner:
License Region:

Global

CAN106

Description: CAN106 is a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 in the complement system.

Indication: PNH and other complement-mediated disorders

Status: Phase 1b/2 in China

Ownership: Greater China right from Wuxi Biologics;Exclusive worldwide right from Privus

CAN103

Indication:
Gaucher Disease
License Partner:
License Region:

Global

CAN103

Description: CAN103 is a recombinant human enzyme replacement therapy (ERT).

Indication: Gaucher disease, one of the most common lysosomal storage disorders (LSDs)

Status: IND Approved

Trial registration: ClinicalTrials.gov NCT05447494  

Ownership: Exclusive global license from WuXi Biologics

CAN107

Indication:
 X-linked hypophosphatemia
License Partner:
License Region:

Global

CAN107

Description: CAN107 is a fibroblast growth factor 23 (FGF23) blocking antibody.

Indication: X-linked hypophosphatemia (XLH), usually diagnosed in children and an inherited disorder characterized by low levels of phosphate in the blood due abnormal kidney processing in the kidneys, leading to soft, weak bones 

Status: Preclinical

Ownership: Exclusive global license from WuXi Biologics and Privus

CAN104

Indication:
Fabry Disease
License Partner:
License Region:

Global

CAN104

Description: CAN104 is a recombinant human enzyme replacement therapy (ERT).

Indication: Fabry Disease

Status: Preclinical

Ownership: Exclusive global license from WuXi Biologics

CAN105

Indication:
Hemophilia A
License Partner:
License Region:

Greater China

CAN105

Description: CAN105 is a bispecific antibody.

Indication: Hemophilia A, a genetic deficiency in clotting factor VIII which causes increased bleeding and usually affects males

Status: Preclinical

Ownership: Exclusive Greater China license from WuXi Biologics

Gene Therapy
Pipeline
Pre-clinical
Ph 1
Ph 2
Ph 3
Approval

CAN201

Indication:
Fabry Disease
License Partner:
License Region:

Global

CAN201:

Description: CAN201 is a gene therapy program utilizing adeno-associated virus (AAV) sL65 capsid.

Indication: Fabry disease, also called Anderson-Fabry disease, a rare inherited lysosomal storage disorder (LSD) of glycosphingolipid (fat) metabolism resulting from the absent or markedly deficient activity of the lysosomal enzyme, α-galactosidase A (α-Gal A)

Status: Preclinical

Ownership: Exclusive global license to sL65 capsid from LogicBio Therapeutics

CAN202

Indication:
Pompe Disease
License Partner:
License Region:

Global

CAN202:

Description: CAN202 is a gene therapy program utilizing adeno-associated virus (AAV) sL65 capsid.

Indication: Pompe disease, also called Glycogen storage disease type II, an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body, caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme

Status: Preclinical

Ownership: Exclusive global license to sL65 capsid from LogicBio Therapeutics

Undisclosed®

Indication:
Neuromuscular Disorders
License Partner:
License Region:

Global

Undisclosed®

Indication:
Duchenne Syndrome
License Partner:
License Region:

Global

Other Onc.
Pipeline
Pre-clinical
Ph 1
Ph 2
Ph 3
Approval

CaphosolTM

Indication:
Oral Mucositis
License Partner:
License Region:

Global

Nerlynx® (Neratinib)

Indication:
HER2+ Breast Cancer
License Partner:
License Region:

Hong Kong, Taiwan, Macau

Indication:
HER2+ Metastatic Breast Cancer
License Partner:
License Region:

Hong Kong, Taiwan, Macau